Prudential Financial Inc Bei Gene, Ltd. Transaction History

Prudential Financial Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	BUY	$189.18 - $286.44 $26,485 - $40,101	140 Added 4.81%	3,048 $873,000
Q2 2020 Aug 12, 2020	SELL	$123.9 - $195.41 $37,170 - $58,623	-300 Reduced 9.35%	2,908 $547,000
Q1 2020 May 12, 2020	SELL	$121.84 - $173.19 $2,680 - $3,810	-22 Reduced 0.68%	3,208 $394,000
Q4 2019 Feb 11, 2020	BUY	$115.78 - $208.34 $11,578 - $20,834	100 Added 3.19%	3,230 $535,000
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $21,709 - $26,692	180 Added 6.1%	3,130 $383,000
Q2 2019 Aug 08, 2019	BUY	$113.99 - $146.86 $8,093 - $10,427	71 Added 2.47%	2,950 $0
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $76,639 - $94,741	624 Added 27.67%	2,879 $0
Q4 2018 Feb 07, 2019	BUY	$107.01 - $175.15 $241,307 - $394,963	2,255 New	2,255 $316,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.